Slowdown in approvals not safety related: FDA
James G. Dickinson
December 01 2006
FDA Office of New Drugs director John Jenkins said concerns over drug safety and "gaming" of the review clock were ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.